Latest United States Startup Funding Rounds
Startup funding in United States: recent rounds, the companies behind them and their participating investors.
- Rounds
- 2,242 Jan 1 – Oct 29, 2026
- Disclosed funding
- $257.7B 1862 disclosed amounts
- Median round
- $24M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| DC Agentic Commerce Marketing platform for AI-powered commerce | Undisclosed | Undisclosed | Enterprise software | United States | Investors | |
| V Provides stablecoin-powered financial infrastructure for global businesses | $20M | Series B | Fintech | United States | Investors | |
| N Develops implant for treating articular cartilage defects in the knee | $4.1M | Seed2Seed | Biotech | United States | Investors | |
| AP Develops, constructs, owns, and operates renewable energy assets | $200M | StrategicUndisclosed | Climate tech | United States | Investors | |
| V Provides intelligent software platforms for oncology care | $43M | Undisclosed | Healthtech | United States | Investors | |
 Zepo IntelligenceCompany profile Zepo Intelligence develops workspace security software combining human-risk management and threat monitoring. Zepo Intelligence develops workspace security software combining human-risk management and threat monitoring. | $15M | Seed | Cybersecurity | United States | Investors | |
| MT Mirador TherapeuticsCompany profile Develops next-generation therapies for immune-mediated inflammatory and fibrotic diseases Develops next-generation therapies for immune-mediated inflammatory and fibrotic diseases | $250M | Series B | Biotech | United States | Investors | |
 Allos AICompany profile Causal AI and pharmaceutical development services for reformulating complex drugs and directing laboratory studies. Causal AI and pharmaceutical development services for reformulating complex drugs and directing laboratory studies. | $5M | Seed | AI | United States | Investors | |
| TB Trailhead BiosystemsCompany profile Develops human cells with defined molecular and functional properties for drug discovery and regenerative medicine Develops human cells with defined molecular and functional properties for drug discovery and regenerative medicine | $20M | Growth | Biotech | United States | Investors | |
| CA Cast AICompany profile Provides automation platform for operating cloud-native and AI workloads at scale Provides automation platform for operating cloud-native and AI workloads at scale | Undisclosed | StrategicUndisclosed | Developer tools | United States | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · From Jan 1, 2026
- 1Y Combinator (YC)
Vera Health, BioStack, Tractian
133rounds3led - 2Andreessen Horowitz (a16z)
Hex, ASI, Eka Robotics
100rounds20led - 3General Catalyst
Hyperbolic, Re:Build, Provision Labs
73rounds8led - 4Alumni Ventures
Maxinsights, Daytona, Chariot Claims
59rounds0led - 5Sequoia Capital
Hex, Warhound, Whop
58rounds9led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.